Study		Expe	rimental			Control				Weight	Weight
	Total		Total Mean	SD	Mean Difference	MD	95%-CI	_	(random)		
g = 12-13months											
Dharmarajan 2021	54	-23.83	18.2200	54	-22.89	17.8400 -		-0.94	[-7.74; 5.86]	0.1%	6.1%
Miglani 2022 Dupi-52	150	-29.84	1.6300	48	-33.90	3.0400	 		[3.16; 4.96]		30.1%
Fixed effect model	204			102			☆		[3.08; 4.87]		
Random effects model									[-1.57; 7.06]		36.2%
Heterogeneity: $I^2 = 51\%$, τ^2	$^{2} = 6.37$	42, p = (0.15						. ,		
g = 6-8months											
Miglani 2022 Dupi-24	143	-30.43	1.5400	111	-33.30	1.8000		2.87	[2.45; 3.29]	39.3%	31.8%
Miglani 2022 Dupi-52		-27.77			-33.30		-		[5.17; 5.89]		
Fixed effect model				222			.		[4.11; 4.66]		
Random effects model									[1.60; 6.81]		63.8%
Heterogeneity: $I^2 = 99\%$, τ^2	$^{2} = 3.49$	76, p < 0	0.01								
Fixed effect model	642			324			♦	4.35	[4.09; 4.61]	100.0%	_
Random effects model								3.85	[1.99; 5.71]		100.0%
Heterogeneity: $I^2 = 97\%$, τ^2	$^{2} = 2.78$	22, p < (0.01						- / -		
Residual heterogeneity: 12							-6 -4 -2 0 2 4 6				

Supplementary Fig. 9. Changes in SNOT-22 scores from baseline in the dupilumab and ESS groups. The mean post-treatment differences at 6 and 12 months [14,15]. SNOT-22, 22-item SinoNasal Outcome Test; ESS, endoscopic sinus surgery; SD, standard deviation; MD, mean difference; CI, confidence interval.